ArticlePharmacoEconomics - open2019

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study.

Luis Manuel Entrenas Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.